Alan Auerbach is the brains and leadership behind Puma Biotechnology PBYI -2.29%, a biopharma acquirer and developer of innovative cancer treatments that has had a great stock run this past week. The Los Angeles-based company’s shares surged 88 percent from Wednesday to Friday, closing the week at $86.75 per share. Today they’re up more than 1%, trading at close to $88 per share. The founder, chairman and CEO’s shares in the company have appreciated by $167 million on the good news, nearly doubling his stake from $185 million to $352 million.
{iframe}http://www.forbes.com/sites/alexmorrell/2013/12/09/biotech-entrepreneurs-fortune-nearly-doubles-after-strong-clinical-trials-for-cancer-treatment/{/iframe}